Sonia Ronconi

Medicine & Life Sciences

1. Multiple Myeloma 100%
2. Stem Cell Transplantation 34%
3. Thalidomide 27%
4. Homologous Transplantation 20%
5. Allogeneic Cells 18%
6. Autologous Transplantation 17%
7. Salvage Therapy 16%
8. Residual Neoplasm 16%
9. Dexamethasone 16%
10. Hematopoietic Stem Cell Transplantation 15%
11. Melphalan 12%
12. Mitoxantrone 12%
13. Philadelphia Chromosome 12%
14. Drug Therapy 10%
15. Bone Marrow 10%
16. Progression-Free Survival 10%
17. Non-Hodgkin's Lymphoma 10%
18. Recurrence 10%
19. VAD combination 10%
20. Transplants 10%
21. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9%
22. Prednisone 9%
23. Survival 9%
24. Chromosome Aberrations 9%
25. Polymerase Chain Reaction 8%
26. Bortezomib 8%
27. Peripheral Blood Stem Cells 8%
28. Busulfan 8%
29. Therapeutics 7%
30. Clinical Studies 7%
31. ibritumomab tiuxetan 7%
32. Imatinib Mesylate 7%
33. Stem Cells 6%
34. Follicular Lymphoma 6%
35. Lenalidomide 6%
36. Peripheral Blood Stem Cell Transplantation 6%
37. Frail Elderly 6%
38. fludarabine 6%
39. Plasmacytoma 5%
40. Patients' Rooms 5%
41. Premedication 5%
42. Osteonecrosis 5%
43. Retinoids 5%
44. Hematologic Neoplasms 5%
45. Midazolam 5%
46. Italy 5%
47. Diphosphonates 5%
48. Needle Biopsy 5%
49. Fentanyl 5%
50. Vincristine 5%